Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 17662577)

1.

Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.

Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL.

Schizophr Res. 2007 Sep;95(1-3):134-42. Epub 2007 Jul 26.

2.

Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol.

Duncan E, Szilagyi S, Schwartz M, Kunzova A, Negi S, Efferen T, Peselow E, Chakravorty S, Stephanides M, Harmon J, Bugarski-Kirola D, Gonzenbach S, Rotrosen J.

Psychiatry Res. 2003 Aug 30;120(1):1-12.

PMID:
14500109
3.

Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.

Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kühn KU.

Biol Psychiatry. 2006 Mar 15;59(6):536-45. Epub 2005 Sep 1.

PMID:
16139819
4.

A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics.

Kumari V, Antonova E, Geyer MA, Ffytche D, Williams SC, Sharma T.

Int J Neuropsychopharmacol. 2007 Aug;10(4):463-77. Epub 2006 Aug 21.

PMID:
16923324
5.

Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia.

Quednow BB, Frommann I, Berning J, Kühn KU, Maier W, Wagner M.

Biol Psychiatry. 2008 Nov 1;64(9):766-73. doi: 10.1016/j.biopsych.2008.04.019. Epub 2008 Jun 2.

PMID:
18514166
6.

Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.

Kishi T, Moriwaki M, Kitajima T, Kawashima K, Okochi T, Fukuo Y, Furukawa O, Naitoh H, Fujita K, Iwata N.

Psychopharmacology (Berl). 2010 Apr;209(2):185-90. doi: 10.1007/s00213-010-1787-x. Epub 2010 Feb 23.

PMID:
20177883
7.
8.
9.

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J.

J Clin Psychiatry. 2006 Oct;67(10):1511-21.

PMID:
17107241
10.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2002 Feb;159(2):255-62. Erratum in: Am J Psychiatry 2002 Dec;159(12):2132.

PMID:
11823268
11.

Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.

Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J.

Am J Psychiatry. 2007 Oct;164(10):1585-92. Erratum in: Am J Psychiatry. 2007 Nov;164(11):1766.

PMID:
17898351
12.

(+/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics.

Cilia J, Hatcher P, Reavill C, Jones DN.

J Psychopharmacol. 2007 May;21(3):302-11.

PMID:
17591657
13.

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.

Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chakos M, Lieberman JA.

Psychiatr Serv. 2001 Nov;52(11):1510-4.

PMID:
11684748
14.

Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission.

Perry W, Feifel D, Minassian A, Bhattacharjie I, Braff DL.

Am J Psychiatry. 2002 Aug;159(8):1375-81.

PMID:
12153831
15.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA.

Am J Psychiatry. 2002 Jun;159(6):1018-28.

PMID:
12042192
16.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
17.

Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia.

Duncan EJ, Szilagyi S, Efferen TR, Schwartz MP, Parwani A, Chakravorty S, Madonick SH, Kunzova A, Harmon JW, Angrist B, Gonzenbach S, Rotrosen JP.

Psychopharmacology (Berl). 2003 Apr;167(1):63-71. Epub 2003 Mar 11.

PMID:
12632245
18.

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Apr;62(4):231-8.

PMID:
11379836
19.

One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.

Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A; HGGN Study Group.

Schizophr Res. 2006 Jan 1;81(1):1-15. Epub 2005 Oct 3.

PMID:
16202565
20.

Olanzapine: an updated review of its use in the management of schizophrenia.

Bhana N, Foster RH, Olney R, Plosker GL.

Drugs. 2001;61(1):111-61. Review.

PMID:
11217867
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk